B2PRIME
B2B Prime Services SC Ltd, a multi-asset Prime of Prime liquidity provider, has achieved another significant regulatory milestone by obtaining a security dealer license in Seychelles. This marks the third license for B2Prime, following those in Cyprus and Mauritius. These jurisdictions serve as key hubs with a high concentration of brokers, and B2Prime is dedicated to serving regulated market participants not only in these locations but also throughout Europe. This latest license underscores B2Prime's commitment to providing trusted and compliant services to its global client base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430008885/en/
B2Prime, a globally renowned multi-asset Prime of Prime liquidity provider, has obtained a security dealer license in Seychelles, expanding its global operations and opening doors to its top-tier liquidity services for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. (Photo: Business Wire)
Seychelles, recognised as a crucial hub for brokers, provides B2Prime with a strategic platform to distribute liquidity locally across all regulated companies.
The newly acquired security dealer license enables the B2Prime group to engage in crucial financial activities, such as negotiating and entering agreements for acquiring, disposing of, subscribing for, or underwriting securities. Additionally, it allows to manage securities transactions, handle sales, and manage portfolios of securities on behalf of the clients.
This significant development will greatly enhance the ability to operate efficiently within global markets, backed by a robust legal framework to offer these services under the strict regulatory oversight of the Seychelles Financial Services Authority (SFSA).
Importance of Seychelles License for B2Prime Clients
Seychelles is becoming an attractive location for brokerages, thanks to its strategic placement between Africa, Asia, and the Middle East and its supportive financial climate. With 182 brokers already registered in Seychelles, there is a clear need for a local liquidity partner that can streamline operations and offer advanced financial and technology solutions.
In response to this demand, B2Prime has strategically expanded its presence by acquiring a security dealer license from the Seychelles Financial Services Authority (SFSA), the regulatory body responsible for the licensing and supervision of financial service providers, including security dealers.
This development eliminates the need for local companies to seek out or connect with liquidity providers in distant financial hubs. Instead, they can directly access B2Prime’s extensive Prime of Prime level liquidity.
B2Prime offers over 225 instruments across six asset classes in CFDs, including FOREX, Cryptos, Spot Indices, Precious Metals, Commodities, and NDFs, all through a single margin account. B2Prime clients benefit from deep liquidity pools sourced from Tier-1 providers, which ensure tight spreads and ultra-fast execution. Connectivity options, including OneZero, PXM, Centroid, T4B, FIX API, and cTrader, further facilitate seamless integration and efficiency.
“Establishing our operations in Seychelles opens doors to our Prime of Prime liquidity and enhanced service levels for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. This step forward aligns perfectly with our goal of providing top-tier financial services worldwide and enables us to offer even greater reliability and seize new opportunities in global markets.”
– Eugenia Mykulyak, Founder & Executive Director of B2Prime
Robust Financial Performance and Future Outlook
Following the strategic initiatives, B2Prime has recently disclosed the financial results for its parent company, B2B Prime Services EU, which highlights robust financial growth in the first quarter of 2024. Total assets in Cyprus surged to €28,969,690.98, a 40.32% increase from the previous year. Client assets held for trading also increased by 47.6% to €26,840,460.11.
In the same period, the shareholders' equity rose by 8%, with year-on-year comparisons showing a 68% growth in total assets and a 64% increase in client assets held for trading. Notably, shareholders' equity experienced an impressive 289% surge. Regulatory Capital Adequacy dramatically improved, too, with B2Prime's own funds soaring nearly 600% from €503,000 to €2,728,000, far exceeding regulatory minimums with CET1 and Tier 1 ratios significantly above the required standards.
These figures highlight a strong balance sheet and show B2Prime’s ongoing devotion to growth and reliability. Soon, the company will also disclose the fiscal report for B2Prime Mauritius, which will further validate its position as a credible and reliable service provider to clients worldwide.
Final Remarks
B2Prime has been actively expanding its global footprint since its establishment in Cyprus in 2020 and Mauritius in 2023. The ongoing strategy aims to position B2Prime as a trusted partner in key financial jurisdictions worldwide. The recent acquisition of a security dealer license in Seychelles is a continuation of these efforts to offer Prime of Prime financial services and exclusive tools to local businesses in Seychelles, enhancing their capabilities and potential to succeed in the global marketplace.
The company is thrilled to start operating as a trusted liquidity provider in Seychelles and partner with local businesses!
Reach out today for market-leading liquidity solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430008885/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
